Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Helen Garner’s ‘unsparing’ diary collection becomes first to win prestigious Baillie Gifford non-fiction prize | Ents & Arts News

    Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength

    Malaysian rapper Namewee detained in murder investigation of Taiwanese influencer

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest VKontakte
    Sg Latest NewsSg Latest News
    • Home
    • Politics
    • Business
    • Technology
    • Entertainment
    • Health
    • Sports
    Sg Latest NewsSg Latest News
    Home»Health»Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength
    Health

    Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength

    AdminBy AdminNo Comments18 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    • Third quarter revenue of $288 million, with 59% gross margin 
    • Year to date cash flow from operations of $214 million and free cash flow of $173 million*
    • Sold over 12.5 million branded products in the third quarter, up 7% compared to last year

    TALLAHASSEE, Fla., Nov. 5, 2025 /PRNewswire/ — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended September 30, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.

    Q3  2025 Financial and Operational Highlights*

    • Revenue of $288 million, with 94% of revenue from retail sales.
    • Achieved gross margin of 59%, with GAAP gross profit of $170 million.
    • Reported net loss attributable to common shareholders of $27 million. Adjusted net loss of $12 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
    • Achieved adjusted EBITDA of $103 million*, or 36% of revenue, up 7% year over year.
    • Generated cash flow from operations of $77 million and free cash flow of $64 million*.
    • Cash at quarter end was $458 million.
    • Added Chief Financial Officer Jan Reese to the leadership team and appointed Matthew Foulston to the Board of Directors.
    • Rewards program members reached 820,000 members as of September 30, 2025. Loyalty members accounted for 77% of transactions during the third quarter.
    • Launched new Roll One Clutch All In One vapes in Florida, selling out in under two weeks.
    • Expanded distribution of Onward premium THC beverages in Florida and Illinois, launched new Upward THC energy drinks, and introduced five new 10mg flavors.
    • Opened one dispensary in Cincinnati, Ohio and relocated one dispensary to Bisbee, Arizona.

    *See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

    Recent Developments

    • Announced planned redemption of $368 million of senior secured notes due 2026.
    • Launched new mobile app serving Florida customers enabling patients to browse and reserve products, view promotions, and check rewards status through a seamless digital experience.
    • Currently operate 232 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.

    Management Commentary 

    “Our 2025 strategic plan is delivering results, with demonstrable progress on reform, customers, distribution, and branded products,” said Kim Rivers, Trulieve CEO. “Significant flexibility in our core business and strong cash generation continue to set us apart in a dynamic market.”

    Financial Highlights*

    Results of Operations

    For the Three Months Ended

    For the Nine Months Ended

    (Figures in millions except per share data)

    September
    30, 2025

    September
    30, 2024

    %
    Better /
    (Worse)

    June 30,
    2025

    %
    Better /
    (Worse)

    September
    30, 2025

    September
    30, 2024

    %
    Better /
    (Worse)

    Revenue

    $

    288

    $

    284

    1 %

    $

    302

    (5 %)

    $

    888

    $

    885

    — %

    Gross profit

    $

    170

    $

    173

    (2 %)

    $

    183

    (7 %)

    $

    536

    $

    529

    1 %

    Gross margin %


    59 %


    61 %



    61 %



    60 %


    60 %


    Operating expenses

    $

    128

    $

    173

    26 %

    $

    130

    2 %

    $

    408

    $

    432

    6 %

    Operating expenses %


    44 %


    61 %



    43 %



    46 %


    49 %


    Net loss**

    $

    (27)

    $

    (60)

    55 %

    $

    (14)

    (95 %)

    $

    (73)

    $

    (95)

    23 %

    Net loss continuing
         operations

    $

    (24)

    $

    (60)

    61 %

    $

    (16)

    (50 %)

    $

    (72)

    $

    (94)

    24 %

    Adjusted net (loss) income

    $

    (12)

    $

    (12)

    (5 %)

    $

    (8)

    (61 %)

    $

    (24)

    $

    (22)

    (8 %)

    Basic and diluted shares
         outstanding


    191


    190



    191



    191


    190


    EPS continuing operations

    $

    (0.11)

    $

    (0.32)

    64 %

    $

    (0.07)

    (62 %)

    $

    (0.35)

    $

    (0.52)

    34 %

    Adjusted EPS

    $

    (0.07)

    $

    (0.06)

    (5 %)

    $

    (0.04)

    (61 %)

    $

    (0.12)

    $

    (0.12)

    (7 %)

    Adjusted EBITDA

    $

    103

    $

    96

    7 %

    $

    111

    (7 %)

    $

    322

    $

    309

    4 %

    Adjusted EBITDA Margin %


    36 %


    34 %



    37 %



    36 %


    35 %

















    *See “Non-GAAP Financial Measures” below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

    **Net loss attributable to common shareholders which excludes non-controlling interest.

    Conference Call
    The Company will host a conference call and live audio webcast on November 5, 2025, at 8:30 A.M. Eastern time, to discuss its third quarter 2025 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

    North American toll free: 1-844-824-3830


    Passcode: 9870622




    International: 1-412-542-4136


    Passcode: 9870622

    A live audio webcast of the conference call will be available at: Trulieve Third Quarter 2025 Results Call

    A powerpoint presentation and archived replay of the webcast will be available at: https://investors.trulieve.com/events

    The Company’s Form 10-Q for the quarter ended September 30, 2025 will be available on the SEC’s website or at https://investors.trulieve.com/quarterly-results. The Company’s Management’s Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company’s profile on https://www.sedarplus.ca and on its website at https://investors.trulieve.com/quarterly-results. This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

    Trulieve Cannabis Corp.

    Condensed Consolidated Balance Sheets (Unaudited)

    (in millions, except for share data) 



    September 30,
    2025


    December 31,
    2024

    ASSETS




    Current Assets:




    Cash and cash equivalents

    $                449.2


    $                238.8

    Short-term investments

    —


    60.4

    Restricted cash – current

    0.9


    0.9

    Accounts receivable, net

    10.5


    8.3

    Inventories

    243.3


    231.4

    Income tax receivable

    7.4


    10.0

    Prepaid expenses

    20.7


    23.0

    Other current assets

    22.1


    26.2

    Notes receivable – current portion, net

    1.6


    4.8

    Assets associated with discontinued operations

    0.9


    0.9

    Total current assets

    756.4


    604.6

    Property and equipment, net

    694.0


    716.1

    Right of use assets – operating, net

    110.7


    119.5

    Right of use assets – finance, net

    60.9


    64.4

    Intangible assets, net

    815.3


    859.5

    Goodwill

    483.9


    483.9

    Restricted cash

    7.5


    —

    Notes receivable, net

    0.5


    0.5

    Other assets

    10.4


    19.8

    Long-term assets associated with discontinued operations

    1.9


    2.0

    TOTAL ASSETS

    $            2,941.6


    $             2,870.3

    LIABILITIES




    Current Liabilities:




    Accounts payable and accrued liabilities

    $                  81.3


    $                  94.0

    Deferred revenue

    8.9


    8.0

    Notes payable – current portion

    3.7


    3.4

    Operating lease liabilities – current portion

    12.8


    12.1

    Finance lease liabilities – current portion

    10.4


    9.5

    Construction finance liabilities – current portion

    2.3


    1.9

    Contingencies

    0.8


    6.3

    Liabilities associated with discontinued operations

    3.9


    3.1

    Total current liabilities

    124.1


    138.5

    Long-Term Liabilities:




    Private placement notes, net

    366.1


    364.8

    Notes payable, net

    107.7


    111.9

    Operating lease liabilities

    110.5


    117.5

    Finance lease liabilities

    65.2


    67.7

    Construction finance liabilities

    134.3


    135.5

    Deferred tax liabilities

    181.9


    196.5

    Uncertain tax position liabilities

    616.3


    445.2

    Other long-term liabilities

    11.8


    5.0

    Long-term liabilities associated with discontinued operations

    37.4


    38.6

    TOTAL LIABILITIES

    $            1,755.3


    $             1,621.2

    SHAREHOLDERS’ EQUITY




    Common stock, no par value; unlimited shares authorized. 191,144,583 and
    191,005,940 shares issued and outstanding as of September 30,
    2025 and December 31, 2024, respectively.

    $                      —


    $                      —

    Additional paid-in-capital

    2,073.0


    2,057.0

    Accumulated deficit

    (869.2)


    (795.7)

    Non-controlling interest

    (17.5)


    (12.3)

    TOTAL SHAREHOLDERS’ EQUITY

    1,186.3


    1,249.0

    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

    $            2,941.6


    $             2,870.3

    Trulieve Cannabis Corp.

    Condensed Consolidated Statements of Operations (Unaudited)

    (in millions, except for share data)



    Three Months Ended
    September 30,


    Nine Months Ended
    September 30,


    2025


    2024


    2025


    2024

    Revenue

    $       288.2


    $       284.3


    $       888.0


    $       885.3

    Cost of goods sold

    118.3


    111.0


    352.0


    356.6

    Gross profit

    169.9


    173.3


    536.0


    528.7

    Expenses:








    Selling, general, and administrative

    99.0


    148.6


    318.9


    352.5

    Depreciation and amortization

    29.5


    28.3


    88.2


    84.2

    Impairment and other charges, net of (recoveries)

    (0.9)


    (4.3)


    0.7


    (4.4)

    Total expenses

    127.6


    172.7


    407.8


    432.3

    Income from operations

    42.2


    0.6


    128.2


    96.5

    Other income (expense):








    Interest expense, net

    (16.1)


    (17.5)


    (48.8)


    (47.6)

    Interest income

    4.4


    4.2


    11.1


    11.5

    Other expense, net

    (1.2)


    (0.2)


    (2.0)


    (4.8)

    Total other expense, net

    (12.9)


    (13.5)


    (39.7)


    (40.9)

    Income (loss) before provision for income taxes

    29.3


    (12.8)


    88.5


    55.6

    Provision for income taxes

    53.0


    47.4


    160.2


    150.0

    Net loss from continuing operations

    (23.7)


    (60.2)


    (71.7)


    (94.4)

    Net loss from discontinued operations, net of tax benefit (provision) of $0, $0,
         $(441), and $0, respectively

    (5.0)


    (1.6)


    (7.0)


    (4.6)

    Net loss

    (28.8)


    (61.9)


    (78.7)


    (99.0)

    Less: net loss attributable to non-controlling interest from continuing operations

    (1.9)


    (1.7)


    (5.2)


    (3.7)

    Net loss attributable to common shareholders

    $        (26.8)


    $        (60.2)


    $        (73.5)


    $        (95.3)









    Earnings Per Share








    Net loss per share – Continuing operations:








    Basic and diluted

    $        (0.11)


    $        (0.32)


    $        (0.35)


    $        (0.52)

    Net loss per share – Discontinued operations:








    Basic and diluted

    $        (0.03)


    $        (0.01)


    $        (0.04)


    $        (0.02)

    Weighted average number of common shares used in computing net loss per
         share:








    Basic and diluted

    191.2


    190.2


    191.2


    190.0

    Trulieve Cannabis Corp.

    Condensed Consolidated Statements of Cash Flows (Unaudited)

    (in millions)



    Three Months Ended
    September 30,


    Nine Months Ended
    September 30,


    2025


    2024


    2025


    2024

    Cash flows from operating activities








    Net loss

    $            (28.8)


    $            (61.9)


    $            (78.7)


    $            (99.0)

    Adjustments to reconcile net loss to net cash provided by operating
    activities:








    Depreciation and amortization

    29.5


    28.3


    88.2


    84.2

    Depreciation included in cost of goods sold

    13.9


    13.3


    41.5


    40.1

    Impairment and other charges, net of (recoveries)

    2.6


    (4.3)


    2.5


    (4.4)

    Share-based compensation

    5.8


    5.5


    16.5


    15.6

    Deferred income taxes

    (4.7)


    (6.2)


    (14.7)


    (2.7)

    Other non-cash changes

    3.7


    3.2


    16.0


    14.1

    Changes in operating assets and liabilities:








    Inventories

    (1.8)


    (13.3)


    (11.9)


    (8.3)

    Accounts receivable

    —


    (1.5)


    (3.4)


    (0.7)

    Other assets

    4.7


    3.8


    3.3


    (7.0)

    Accounts payable and accrued liabilities

    0.3


    4.9


    (11.6)


    4.6

    Income tax receivable / payable

    (0.1)


    0.5


    2.6


    (4.3)

    Other liabilities

    (4.9)


    2.5


    (13.7)


    (1.1)

    Uncertain tax position liabilities

    56.6


    51.0


    171.1


    203.8

    Proceeds received from insurance for operating expenses

    —


    4.4


    5.7


    5.9

    Net cash provided by operating activities

    76.8


    30.3


    213.6


    240.8

    Cash flows from investing activities








    Purchases of property and equipment

    (12.3)


    (38.1)


    (40.8)


    (79.9)

    Purchases of internal use software

    (4.3)


    (6.8)


    (12.6)


    (18.3)

    Purchases of short-term investments

    —


    (80.0)


    —


    (80.0)

    Maturities of short-term investments

    (0.4)


    —


    60.0


    —

    Other purchases and payments

    0.1


    (7.1)


    (0.1)


    (7.6)

    Other proceeds

    1.5


    0.5


    12.9


    2.4

    Net cash provided by (used in) investing activities

    (15.4)


    (131.5)


    19.4


    (183.4)

    Cash flows from financing activities








    Payments on long-term borrowings

    (2.0)


    (2.3)


    (7.5)


    (6.4)

    Payments for taxes related to net share settlement of equity awards

    (0.2)


    (12.2)


    (0.5)


    (12.3)

    Other payments and distributions

    (2.6)


    (1.9)


    (7.1)


    (11.7)

    Proceeds from equity exercises

    —


    —


    —


    0.2

    Other proceeds

    —


    —


    —


    3.0

    Net cash used in financing activities

    (4.8)


    (16.4)


    (15.1)


    (27.1)

    Net increase in cash, cash equivalents, and restricted cash

    56.6


    (117.5)


    217.9


    30.3

    Cash, cash equivalents, and restricted cash, beginning of period

    401.0


    356.1


    239.7


    208.0

    Cash and cash equivalents of discontinued operations, beginning of period

    —


    —


    —


    0.3

    Less: cash and cash equivalents of discontinued operations, end of period

    —


    —


    —


    —

    Cash, cash equivalents, and restricted cash, end of period

    $            457.6


    $            238.6


    $            457.6


    $            238.6

    The condensed consolidated statements of cash flows include continuing operations and discontinued operations for the periods presented.

    Non-GAAP Financial Measures (Unaudited)

    In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, adjusted net (loss) income, adjusted net (loss) income per diluted share, and free cash flow.

    The Company calculates EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization; adjusted EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization and also excludes certain extraordinary items; EBITDA margin as EBITDA as % of revenue; adjusted EBITDA margin as adjusted EBITDA as % of revenue; adjusted net income (loss) as net income (loss) less certain extraordinary items; adjusted EPS as adjusted net income (loss) divided by basic and diluted shares outstanding; and free cash flow as cash flow from operations less capital expenditures.

    Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures are not, and should not be considered as, measures of liquidity. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.

    Reconciliation of Non-GAAP EBITDA and Adjusted EBITDA (Unaudited)

    The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP EBITDA and Adjusted EBITDA for each of the periods presented:

    (Amounts expressed in millions of United States dollars) 

    Three Months Ended

    For the Nine Months Ended

    September
    30, 2025

    September
    30, 2024

    June 30,
    2025

    September
    30, 2025

    September
    30, 2024

    Net loss attributable to common shareholders

    $

    (26.8)

    $

    (60.2)

    $

    (13.8)

    $

    (73.5)

    $

    (95.3)

    Add (deduct) impact of:











    Interest expense, net

    $

    16.1

    $

    17.5

    $

    16.4

    $

    48.8

    $

    47.6

    Interest income

    $

    (4.4)

    $

    (4.2)

    $

    (3.6)

    $

    (11.1)

    $

    (11.5)

    Provision for income taxes

    $

    53.0

    $

    47.4

    $

    54.7

    $

    160.2

    $

    150.0

    Depreciation and amortization

    $

    29.5

    $

    28.3

    $

    29.4

    $

    88.2

    $

    84.2

    Depreciation included in cost of goods sold

    $

    13.9

    $

    13.3

    $

    13.7

    $

    41.5

    $

    40.1

    EBITDA (Non-GAAP)

    $

    81.3

    $

    42.1

    $

    96.8

    $

    254.1

    $

    215.0

    EBITDA Margin (Non-GAAP)


    28 %


    15 %


    32 %


    29 %


    24 %












    Impairment and other charges, net of (recoveries)

    $

    (0.9)

    $

    (4.3)

    $

    (0.3)

    $

    0.7

    $

    (4.4)

    Campaign and political contributions

    $

    6.3

    $

    48.4

    $

    4.4

    $

    33.7

    $

    62.7

    Acquisition, transaction, and other non-recurring costs

    $

    3.8

    $

    2.6

    $

    1.6

    $

    8.5

    $

    10.6

    Share-based compensation

    $

    5.8

    $

    5.5

    $

    6.8

    $

    16.5

    $

    15.6

    Other expense (income), net

    $

    1.2

    $

    0.2

    $

    1.0

    $

    2.0

    $

    4.8

    Discontinued operations, net of tax, attributable to
         common shareholders

    $

    5.0

    $

    1.6

    $

    0.3

    $

    7.0

    $

    4.6

    Adjusted EBITDA (Non-GAAP)

    $

    102.7

    $

    96.1

    $

    110.6

    $

    322.5

    $

    308.8

    Adjusted EBITDA Margin (Non-GAAP)


    36 %


    34 %


    37 %


    36 %


    35 %

    Reconciliation of Non-GAAP Adjusted Net (Loss) Income (Unaudited)

    The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP adjusted net (loss) income, for each of the periods presented:


    For the Three Months Ended

    For the Nine Months Ended

    (Amounts expressed in millions of United States dollars)

    September
    30, 2025

    September
    30, 2024

    June 30,
    2025

    September
    30, 2025

    September
    30, 2024

    Net loss attributable to common shareholders

    $

    (26.8)

    $

    (60.2)

    $

    (13.8)

    $

    (73.5)

    $

    (95.3)

    Net loss from discontinued operations, net of tax,
         attributable to common shareholders

    $

    5.0

    $

    1.6

    $

    0.3

    $

    7.0

    $

    4.6

    Adjustment of formerly redeemable non-controlling
         interest to maximum redemption value

    $

    —

    $

    (2.1)

    $

    —

    $

    —

    $

    (9.0)

    Net loss from continuing operations available to common
         shareholders

    $

    (21.8)

    $

    (60.6)

    $

    (13.5)

    $

    (66.5)

    $

    (99.7)

    Add (deduct) impact of:











    Adjustment of formerly redeemable non-controlling
         interest to maximum redemption value

    $

    —

    $

    2.1

    $

    —

    $

    —

    $

    9.0

    Impairment and other charges, net of (recoveries)

    $

    (0.9)

    $

    (4.3)

    $

    (0.3)

    $

    0.7

    $

    (4.4)

    Campaign and political contributions

    $

    6.3

    $

    48.4

    $

    4.4

    $

    33.7

    $

    62.7

    Acquisition, transaction, and other non-recurring costs

    $

    3.8

    $

    2.6

    $

    1.6

    $

    8.5

    $

    10.6

    Adjusted net (loss) income (Non-GAAP)

    $

    (12.5)

    $

    (11.9)

    $

    (7.7)

    $

    (23.6)

    $

    (21.9)

    Reconciliation of Non-GAAP Adjusted Net (Loss) Income Per Diluted Share (Unaudited)

    The following table presents a reconciliation of GAAP net loss attributable to common shareholders per share to non-GAAP adjusted net (loss) income per diluted share, for each of the periods presented:


    For the Three Months Ended

    For the Nine Months Ended

    (Amounts expressed are per share except for shares
         which are in millions)

    September
    30, 2025

    September
    30, 2024

    June 30,
    2025

    September
    30, 2025

    September
    30, 2024

    Net loss attributable to common shareholders

    $

    (0.14)

    $

    (0.32)

    $

    (0.07)

    $

    (0.38)

    $

    (0.50)

    Net loss from discontinued operations, net of tax,
         attributable to common shareholders

    $

    0.03

    $

    0.01

    $

    0.00

    $

    0.04

    $

    0.02

    Adjustment of formerly redeemable non-controlling
         interest to maximum redemption value

    $

    —

    $

    (0.01)

    $

    —

    $

    —

    $

    (0.05)

    Net loss from continuing operations available to common
         shareholders

    $

    (0.11)

    $

    (0.32)

    $

    (0.07)

    $

    (0.35)

    $

    (0.52)

    Add (deduct) impact of:











    Adjustment of formerly redeemable non-controlling
         interest to maximum redemption value

    $

    —

    $

    0.01

    $

    —

    $

    —

    $

    0.05

    Impairment and other charges, net of (recoveries)

    $

    (0.00)

    $

    (0.02)

    $

    (0.00)

    $

    0.00

    $

    (0.02)

    Campaign and political contributions

    $

    0.03

    $

    0.25

    $

    0.02

    $

    0.18

    $

    0.33

    Acquisition, transaction, and other non-recurring costs

    $

    0.02

    $

    0.01

    $

    0.01

    $

    0.04

    $

    0.06

    Adjusted net (loss) income (Non-GAAP)

    $

    (0.07)

    $

    (0.06)

    $

    (0.04)

    $

    (0.12)

    $

    (0.12)

    Basic and diluted shares outstanding


    191.2


    190.2


    191.2


    191.2


    190.0

    Reconciliation of Non-GAAP Free Cash Flow (Unaudited)

    The following table presents a reconciliation of GAAP cash flow from operating activities to non-GAAP free cash flow, for each of the periods presented:


    For the Three Months Ended

    For the Nine Months Ended

    (Amounts expressed in millions of United States dollars)

    September
    30, 2025

    September
    30, 2024

    June 30,
    2025

    September
    30, 2025

    September
    30, 2024

    Cash flow from operating activities

    $

    76.8

    $

    30.3

    $

    86.1

    $

    213.6

    $

    240.8

    Payments for property and equipment

    $

    (12.3)

    $

    (38.1)

    $

    (11.6)

    $

    (40.8)

    $

    (79.9)

    Free cash flow (Non-GAAP)

    $

    64.4

    $

    (7.8)

    $

    74.5

    $

    172.8

    $

    160.9

    Forward-Looking Statements

    This news release includes forward-looking information and statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation (collectively herein referred to as “forward-looking statements”). These forward-looking statements relate to the Company’s expectations or forecasts of business, operations, financial performance, cash flows, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding the Company’s 2025 objectives, growth opportunities, and positioning for the future. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and in our periodic reports subsequently filed with the United States Securities and Exchange Commission and in the Company’s filings on https://www.sedarplus.ca. Although the Company believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking statements. Any forward-looking statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise.

    About Trulieve 

    Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

    Facebook: @Trulieve
    Instagram: @Trulieve
    X: @Trulieve

    Investor Contact 
    Christine Hersey, Vice President of Investor Relations
    +1 (424) 202-0210
    [email protected] 

    Media Contact 
    Phil Buck, APR, Corporate Communications Manager
    +1 (406) 370-6226
    [email protected]

    SOURCE Trulieve Cannabis Corp.



    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Admin
    • Website

    Related Posts

    Natural Field will Launch “Ashwagandha White Paper” at FTA Forum in Hangzhou

    What to know about Dick Cheney’s heart trouble and eventual transplant

    A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND EFFICIENCY IN FIELD EXCELLENCE AT VEEVA COMMERCIAL SUMMIT EUROPE

    As world leaders enter climate talks, people in poverty have the most at stake

    Add A Comment
    Leave A Reply Cancel Reply

    Editors Picks

    Judge reverses Trump administration’s cuts of billions of dollars to Harvard University

    Prabowo jets to meet Xi in China after deadly Indonesia protests

    This HP laptop with an astonishing 32GB of RAM is just $261

    Top Reviews
    9.1

    Review: Mi 10 Mobile with Qualcomm Snapdragon 870 Mobile Platform

    By Admin
    8.9

    Comparison of Mobile Phone Providers: 4G Connectivity & Speed

    By Admin
    8.9

    Which LED Lights for Nail Salon Safe? Comparison of Major Brands

    By Admin
    Sg Latest News
    Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
    • Get In Touch
    © 2025 SglatestNews. All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.